Allena Pharmaceuticals, Inc. filed its 10-K on Mar 31, 2022 for the period ending Dec 31, 2021. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Allena Pharmaceuticals, Inc.
Equities
ALNA
US0181191075
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+15.19% | 12TCr | |
+19.91% | 11TCr | |
+8.24% | 2.28TCr | |
-19.80% | 2.07TCr | |
-16.19% | 1.65TCr | |
-13.45% | 1.64TCr | |
-44.35% | 1.58TCr | |
+2.13% | 1.35TCr | |
+66.67% | 1.17TCr |